Solstice Capital seeks superior venture capital returns for its limited partners through investments in seed- and early-stage companies in the industry areas of alternative energy, education, the environment, life sciences and information technology.
Solstice’s unique assets give it a distinct advantage: a seasoned management team with over 90 years of experience in both venture investing and operations in high-growth companies an emphasis on positive impact investing the appropriate size fund for early-stage companies geographic diversification
From its inception, Solstice has demonstrated its commitment to provide both capital and expert guidance to assist portfolio companies as they deal with the challenges and opportunities of growth.
An early-stage, diversified, positive impact venture fund
Solstice is committed to investing 50% of its capital in information technology and 50% in the following socially responsive investment categories: Alternative Energy The Environment Life Sciences Education
|Regenesis Biomedical||6/2011||Series C||$5.3M||3|
|HTG Molecular Diagnostics||2/2011||Series D||$15.7M||4|
|High Throughput Genomics||2/2011||Series D||$15.7M||5|
|Arxan Technologies||3/2007||Series C||$13M||5|
|Lumigent Technologies||3/2003||Venture Round||$7M||4|